{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:56:11Z","timestamp":1758815771866,"version":"3.37.3"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T00:00:00Z","timestamp":1522281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Kidneys for Life Charity","award":["505256"],"award-info":[{"award-number":["505256"]}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/J010847\/1"],"award-info":[{"award-number":["MR\/J010847\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EU Framework 7 Programme","award":["305608"],"award-info":[{"award-number":["305608"]}]},{"name":"Manchester Academic Healthcare Science Centre","award":["186\/200"],"award-info":[{"award-number":["186\/200"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12,1]]},"DOI":"10.1093\/ndt\/gfy049","type":"journal-article","created":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T12:09:32Z","timestamp":1518696572000},"page":"2145-2155","source":"Crossref","is-referenced-by-count":18,"title":["Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model"],"prefix":"10.1093","volume":"33","author":[{"given":"Patrick","family":"Hamilton","sequence":"first","affiliation":[{"name":"Manchester Institute of Nephrology and Transplantation, Manchester Royal Infirmary, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Durga","family":"Kanigicherla","sequence":"additional","affiliation":[{"name":"Manchester Institute of Nephrology and Transplantation, Manchester Royal Infirmary, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Venning","sequence":"additional","affiliation":[{"name":"Manchester Institute of Nephrology and Transplantation, Manchester Royal Infirmary, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Brenchley","sequence":"additional","affiliation":[{"name":"Manchester Institute of Nephrology and Transplantation, Manchester Royal Infirmary, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Meads","sequence":"additional","affiliation":[{"name":"Academic Unit of Health Economics, Leeds Institute of Health Sciences, Charles Thackrah Building, University of Leeds, Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,3,29]]},"reference":[{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B1","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/ndt\/gfq665","article-title":"The incidence of primary glomerulonephritis worldwide: a systematic review of the literature","volume":"26","author":"McGrogan","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJM199307083290203","article-title":"Prognosis of untreated patients with idiopathic membranous nephropathy","volume":"329","author":"Schieppati","year":"1993","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase a 2Receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B4","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1009742","article-title":"Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy","volume":"364","author":"Stanescu","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B5","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1681\/ASN.2012070730","article-title":"Phospholipase A2 Receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy","volume":"24","author":"Coenen","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B6","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ki.2012.486","article-title":"Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy","volume":"83","author":"Kanigicherla","year":"2013","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B7","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2012030242","article-title":"Antiphospholipase A2 Receptor antibody titer and subclass in idiopathic membranous nephropathy","volume":"23","author":"Hofstra","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/ndt\/gfr371","article-title":"Management of patients with membranous nephropathy","volume":"27","author":"Hofstra","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B9","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.2215\/CJN.07210810","article-title":"Anti-phospholipase A2 Receptor antibodies correlate with clinical status in idiopathic membranous nephropathy","volume":"6","author":"Hofstra","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B10","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.2215\/CJN.10471013","article-title":"Association of Anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy","volume":"9","author":"Bech","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B11","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 Receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B12","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B13","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.2013040430","article-title":"Phospholipase A2 Receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy","volume":"25","author":"Hoxha","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B14","first-page":"186","article-title":"KDIGO clinical practice guideline for glomerulonephritis","volume":"2","author":"Eknoyan","year":"2012","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B15","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1056\/NEJM198404123101503","article-title":"Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy","volume":"310","author":"Ponticelli","year":"1984","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B16","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/ki.1995.453","article-title":"A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy","volume":"48","author":"Ponticelli","year":"1995","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B17","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.V93444","article-title":"A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy","volume":"9","author":"Ponticelli","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B18","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1681\/ASN.2007020166","article-title":"A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy","volume":"18","author":"Jha","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B19","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1053\/j.ajkd.2008.04.013","article-title":"Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial","volume":"52","author":"Dussol","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B20","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1440-1797.2007.00822.x","article-title":"Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome","volume":"12","author":"Chan","year":"2007","journal-title":"Nephrology (Carlton)"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B21","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/sj.ki.5002215","article-title":"Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial","volume":"71","author":"Praga","year":"2007","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/sj.ki.5002664","article-title":"Tacrolimus in membranous nephropathy","volume":"73","author":"Wetzels","year":"2008","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000348570","article-title":"Effect of prolonged tacrolimus treatment in idiopathic membranous nephropathy with nephrotic syndrome","volume":"91","author":"Yuan","year":"2013","journal-title":"Pharmacology"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B24","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2215\/CJN.01180307","article-title":"Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy","volume":"2","author":"Cravedi","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B25","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B26","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B27","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B28","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"GEMRITUX study group. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B29","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0272989X9301300409","article-title":"Markov models in medical decision making a practical guide. medical decision making","volume":"13","author":"Sonnenberg","year":"1993","journal-title":"Med Decis Making"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B30","doi-asserted-by":"crossref","first-page":"iii108","DOI":"10.1093\/ndt\/gfv171.12","article-title":"Results of survey on management of membranous nephropathy in the United Kingdom *on behalf of the UK MN RADAR steering group","volume":"30","author":"Kanigicherla","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B31","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/ndt\/gfv435","article-title":"Long-term outcomes of persistent disease and relapse in primary membranous nephropathy","volume":"31","author":"Kanigicherla","year":"2016","journal-title":"Nephrol Dialysis Transplant"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000370271","article-title":"UK Renal Registry 17th Annual Report: Chapter 1 UK renal replacement therapy incidence in 2013: National and Centre-specific Analyses","volume":"129","author":"Gilg","year":"2015","journal-title":"Nephron"},{"author":"Office of National Statistics","key":"key\n\t\t\t\t2018120219034121800_gfy049-B33"},{"author":"NHS Reference Costs 2014 to 2015","key":"key\n\t\t\t\t2018120219034121800_gfy049-B34"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B35","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"author":"Drugs and pharmaceutical electronic market information (eMit)","key":"key\n\t\t\t\t2018120219034121800_gfy049-B36"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B37","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2015","edition":"69th edn."},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B38","doi-asserted-by":"crossref","first-page":"e8933","DOI":"10.1371\/journal.pone.0008933","article-title":"The average body surface area of adult cancer patients in the UK: a multicentre retrospective study","volume":"5","author":"Sacco","year":"2010","journal-title":"PLoS ONE"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B39","doi-asserted-by":"crossref","first-page":"e1001307","DOI":"10.1371\/journal.pmed.1001307","article-title":"A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments","volume":"9","author":"Wyld","year":"2012","journal-title":"PLoS Med"},{"year":"1999","author":"Kind","key":"key\n\t\t\t\t2018120219034121800_gfy049-B40"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B41","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1524-4733.2008.00352.x","article-title":"Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available)","volume":"11","author":"Ara","year":"2008","journal-title":"Value Health"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B42","doi-asserted-by":"crossref","first-page":"e37763","DOI":"10.1371\/journal.pone.0037763","article-title":"Proteinuria is associated with quality of life and depression in adults with primary glomerulopathy and preserved renal function","volume":"7","author":"Lib\u00f3rio","year":"2012","journal-title":"PLoS ONE"},{"author":"NICE","key":"key\n\t\t\t\t2018120219034121800_gfy049-B43"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B44","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/nep.12955","article-title":"Intravenous pulse cyclophosphamide and steroids induce immunological and clinical remission in new-incident and relapsing primary membranous nephropathy","volume":"23","author":"Kanigicherla","year":"2018","journal-title":"Nephrology (Carlton)"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B45","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/(SICI)1099-1050(199812)7:8<723::AID-HEC392>3.0.CO;2-O","article-title":"Confidence intervals or surfaces? Uncertainty on the cost\u2010effectiveness plane","volume":"7","author":"Briggs","year":"1998","journal-title":"Health Econ"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B46","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/hec.903","article-title":"Cost-effectiveness acceptability curves\u2013facts, fallacies and frequently asked questions","volume":"13","author":"Fenwick","year":"2004","journal-title":"Health Econ"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B47","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0272989X12454579","article-title":"Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7","volume":"32","author":"Eddy","year":"2012","journal-title":"Med Decis Making"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B48","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B49","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B50","first-page":"909","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","author":"Buch","year":"2011","journal-title":"BMJ Publishing Group Ltd and European League against Rheumatism"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B51","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.ki.5002395","article-title":"Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future","volume":"72","author":"Walsh","year":"2007","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B52","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1164\/rccm.200507-1144OC","article-title":"Rituximab for refractory Wegener\u2019s granulomatosis","volume":"173","author":"Keogh","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B53","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1093\/ndt\/gfr137","article-title":"Successful outcome using rituximab as the only immunomodulation in Henoch-Schonlein purpura: case report","volume":"26","author":"Pillebout","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B54","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","article-title":"A review of the current use of rituximab in autoimmune diseases","volume":"9","author":"G\u00fcrcan","year":"2009","journal-title":"Int Immunopharmacology"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B55","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1002\/art.24637","article-title":"A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis","volume":"60","author":"Jones","year":"2009","journal-title":"Arthritis Rheum"},{"article-title":"Successful outcome of a corticodependent Henoch-Sch\u00f6nlein purpura adult with rituximab","author":"Pindi","key":"key\n\t\t\t\t2018120219034121800_gfy049-B56","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/619218"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B57","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/art.22046","article-title":"Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment","volume":"54","author":"Smith","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B58","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/rheumatology\/kel098","article-title":"Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab","volume":"45","author":"Stasi","year":"2006","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2018120219034121800_gfy049-B59","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2215\/CJN.08880813","article-title":"Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy","volume":"9","author":"van den Brand","year":"2014","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/33\/12\/2145\/26757429\/gfy049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T11:18:15Z","timestamp":1660475895000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/33\/12\/2145\/4956408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,29]]},"references-count":59,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,3,29]]},"published-print":{"date-parts":[[2018,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfy049","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"type":"print","value":"0931-0509"},{"type":"electronic","value":"1460-2385"}],"subject":[],"published-other":{"date-parts":[[2018,12]]},"published":{"date-parts":[[2018,3,29]]}}}